Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success

Summary

Spherix research indicates that nearly 90% of EU4+UK hematologists now require longer-term efficacy data before referring hemophilia A patients for gene therapy, reflecting higher standards despite continued interest in the modality.